Mary Tilley Jenkins Vogel, M.D. ...

Dr. Mary T Jenkins Vogel, MD

Claim this profile

NorthShore University HealthSystem-Evanston Hospital

Studies Parotid Gland Cancer
Studies Ovarian Cancer
13 reported clinical trials
42 drugs studied

Area of expertise

1Parotid Gland Cancer
Mary T Jenkins Vogel, MD has run 10 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage III
2Ovarian Cancer
Mary T Jenkins Vogel, MD has run 7 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
NorthShore University HealthSystem-Evanston Hospital
Image of trial facility.
NorthShore University HealthSystem-Highland Park Hospital

Clinical Trials Mary T Jenkins Vogel, MD is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2

More about Mary T Jenkins Vogel, MD

Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Mary T Jenkins Vogel, MD has experience with
  • Carboplatin
  • Paclitaxel
  • Olaparib
  • Pembrolizumab
  • Biospecimen Collection
  • Cediranib Maleate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Mary T Jenkins Vogel, MD specialize in?
Is Mary T Jenkins Vogel, MD currently recruiting for clinical trials?
Are there any treatments that Mary T Jenkins Vogel, MD has studied deeply?
What is the best way to schedule an appointment with Mary T Jenkins Vogel, MD?
What is the office address of Mary T Jenkins Vogel, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security